Therapeutic drug monitoring of TNFinhibitors and other therapeutic antibodies.
Develop assays for novel immunotherapy drugs such as pembrolizumab, nivolumab and ipilimumab for monitoring drug levels in patients with lung cancer and malignant melanoma.
Develop assays for measuring rituximab and anti-rituximab for monitoring drug level and anti-drug antibody formation.
Detection of antibodies to transglutaminase in the HUNT4-cohort using an in-house dual label assay in collaborative study “Coeliac disease in HUNT”.
Screening for patient antibodies to HH1, a novel antibody-based drug used in lymphoma clinical trials (Lymrit).
Recent publications
Nome RV, Amundsen EK, Tvedt THA, Fenstad MH, Øie E(2023) [Not Available] Tidsskr Nor Laegeforen, 143(1) DOI 10.4045/tidsskr.22.0658, PubMed 36655958
Bitter H, Warren DJ, Bolstad N, Noraas AL, Ostensen ME(2023) Transplacental passage of belimumab during pregnancy and follow-up of a child exposed in utero Ann Rheum Dis(in press) DOI 10.1136/ard-2022-223684, PubMed 36604152
Bjørlykke KH, Ørbo HS, Tveter AT, Jyssum I, Sexton J, Tran TT, Christensen IE, Kro GB, Kvien TK, Jahnsen J, Munthe LA, Chopra A, Warren DJ, Mjaaland S, Haavardsholm EA, Grødeland G, Provan SA, Vaage JT, Syversen SW, Goll GL, Jørgensen KK(2022) Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study Lancet Rheumatol, 5(1), e36-e46 DOI 10.1016/S2665-9913(22)00330-7, PubMed 36415604